关于先锋

Company Profile

Research cooperation

Research trends

Research strength

Study on Bioequivalence of Lamotrigine Dispersible Tablets in Human

Release time:

2023-07-12

Indications:

1. Epilepsy; 2. Bipolar disorder

Test group:

1

End point indicators:

1

Number of subjects:

Serial number

Enterprise

Number of subjects

1

Anhui Pioneer Pharmaceutical Co., Ltd.

 48 cases

2

Shanghai Ideal Pharmaceutical Co., Ltd.

 48 cases

3

Xi'an Yuanda Detian Pharmaceutical Co., Ltd.

 48 cases

4

Sanjin Group Hunan Sanjin Pharmaceutical Co., Ltd.

 48 cases

5

Zhejiang Huahai Pharmaceutical Co., Ltd.

56 cases
Back →

Related news

2023-07-25

Generic drug development field

2023-07-12

Bioequivalence Study of Oseltamivir Phosphate Capsules in Human

2023-07-12

Study on Bioequivalence of Lamotrigine Dispersible Tablets in Human

2023-07-12

Bioequivalence Study of Sildenafil Citrate Orally Disintegrating Tablets in Human

2023-07-12

Bioequivalence Study of Fenofibrate Capsules in Human